Top 5 CBD products for 50+ year-olds and seniors

Jun 21, 2021 | Oil Drops

There is a lot to be said about CBD products, and there is so much research backing it up to show how to aid certain conditions along with other practices. But can it help with conditions that are often present in over 50s? That is what we will be discussing in this article. Research has shown that CBD is safe to consume[1] by the vast majority of the population[2], including people of the age of 50, so if you thought you may be too old to consume CBD, you would be wrong! Let’s discuss products that could benefit you if you are over the age of 50.

CBD-HQ Oil for seniors

CBD-HQ is short for CBD – Hydroxy-Quinone and has recently been found to be the most effective variant and the highest concentration of CBD, originally discovered by Israeli scientist Professor Raphael Mechoulam.

The Quinone element of the CBD helps it be more easily absorbed into the body. CBD-HQ takes 20 years to develop naturally in the Cannabis L Sativa plant, but recent experiments have managed to speed up the process to only three months. Due to the scarcity of CBD-HQ, there is not as much research that has been carried out, but so far, it has been found to have both anti-cancer and painkilling properties far in excess than other cannabinoids and much more effective than chemotherapy in fighting certain cancers as well as regulating type 2 diabetes without dietary changes.

Type 2 diabetes causes the level of sugar (glucose) in the blood to become too high and may become hard to manage with age. Diabetes, which is a common condition for people over the age of 50. It is an inflammatory condition, and CBD has been found to display anti-inflammatory properties. A study published in 2016 in “Diabetes Care” explains tha CBD has shown promise in reducing insulin resistance[3] as well as moderating blood sugars for people with type 2 not taking insulin, so CBD-HQ could further improve on this.

It is also worth mentioning that the body’s endocannabinoid system plays an integral part in the energy regulation and body metabolism[4], which is important to know for those who are living with diabetes. Studies have shown that the endocannabinoid system sets the sensitivity of the insulin response in adipocytes[5]. In other words the endocannabinoid system[6] plays an important role in how the body responds to insulin, increasing or decreasing insulin sensitivity. If cannabinoids are responsible for this regulation in your body, CBD-HQ could potentially help improve this along with healthy dieting and exercise.

Studies also looked at how CBD-HQ could help relieve chronic pain conditions[7] that many people aged 50 and over experience. These studies included researching cancer pain, fibromyalgia, and neuropathic pain. In the end, they concluded that CBD was very effective in overall pain management, and it didn’t cause negative side effects. Our CBD-HQ drops with MCT oil can work day or night and can achieve a great sense of vitality. The MCT oil comes from a type of fat called medium-chain triglycerides, and it makes the CBD-HQ absorb into your bloodstream quicker. So, perhaps our CBD-HQ 20% MCT Oil Drops could help you.

Senior with hearing loss

CBD Oil for 50 year-olds

Standard CBD oil could also greatly benefit you if you’re over 50. Another common condition many people over the age of 50 experience is obesity. However, there are studies showing that CBD can  help with weight loss[8] along with dieting and exercising because it can boost your metabolism by breaking down the fat cells in our body. We have white fat cells and brown fat cells in our body, and it’s the brown cells that our body uses for energy. However, CBD has been shown to turn white cells into brown cells, which means our body will have more fat to burn while working out.

Another condition over 50s may experience is the nasty condition of COPD (short for chronic obstructive pulmonary disease). A study has shown that CBD can help open up bronchial passages[9], which could help COPD patients breathe more easily[10] and avoid low blood oxygen levels and other complications. Also, another CBD study on mice showed that CBD helped reduce inflammation and improve lung function[11] in mice with damaged lungs.

CBD is great at helping with so many things, but would you guess that hearing would be one of them? Hearing loss[12] increases sharply with age, and nearly 42% of people aged over 50 have some type of hearing loss. Two receptors in the brain have been discovered, known as CB1 and CB2, which respond to the presence of CBD. Research shows that these receptors may play a role in balance and hearing. This has led some to wonder if taking CBD might help with hearing disorders, such as tinnitus[13], although more research still needs to be carried out. Balancing conditions could also include progressive supranuclear palsy, which encompasses conditions such as Parkinson’s and Alzheimer’s as well. We have a range of standard CBD oil products that could potentially help you with some of these conditions.
Seniors experiencing arthritis before CBD products application

Muscle Repair Gel

Muscle soreness or joint pains are common in people over 50, but there are plenty of studies to show CBD potency can improve any muscle pain you may experience. A study explains how CBD isolate spikes our anandamide levels, a chemical used to regulate pain in our body[14]. This is especially interesting for those who feel slight muscle strains during the day.

The Muscle Repair Gel with Aloe Vera and Vaseline by Cannapharma is made to aid in the recuperation and repair of your muscles. It is infused with DMSO, which speeds up the absorption of the product into your blood, like many of our other products. The CBD has also shown many anti-inflammatory properties. The added DMSO works by aiding CBD with increasing the body’s absorption rate of other medications that might also be managing any pain you’re in. Examples of other conditions that DMSO helps manage include chronic pain, headaches, rheumatoid arthritis[15], inflammation and osteoarthritis[16], many conditions that over 50s have to endure, so our muscle repair gel could benefit you.

CBD products for seniors: Dermal Repair Cream Plus

Dermal Repair Cream Plus

So why does our Dermal Repair Cream Plus have a ‘plus’ in the title? Well, that’s because of the added DMSO[17] (short for dimethyl sulfoxide) on top of the CBD and CBG. DMSO particularly helps in pain relief, which could be great for over 50s. Research shows that applying DMSO topically can improve people’s skin and pain they may feel because of it. This means the Dermal Repair Cream Plus is great for speeding up the healing of wounds or burns on the skin as well as relaxing the muscles beneath.

Another huge benefit that CBD and DMSO could provide to over 50s is aiding in treating Alzheimer’s disease[18]. Studies have suggested that DMSO could be used as a treatment[19] for this devastating disease. DMSO is widely used in clinical research, as it is considered to be the immediate cause of cognitive decline and memory dysfunction[20]. This disease is very common as people get older, so perhaps this is another way to help battle the disease along with other treatments.

There is plenty of evidence to suggest CBD has anti-inflammatory benefits. For example, some studies discuss how CBD interferes with the body’s endocannabinoid receptors to reduce inflammation, while another study showed CBD could reduce an acute inflammation[21], often caused by overexertion.

Cannabidiol may also help reduce some factors in high blood pressure (yet another common condition presenting in over 50s), such as stress, anxiety, and poor sleep quality. A study found that CBD may have vasodilatory effects[22] in human and rat arteries. The authors suggest that CBD may improve a person’s blood flow, as it widens their blood vessels. Additionally, another study looked at the effects of a single dose of CBD oil in healthy participants and found that it lowered blood pressure in individuals[23] who were at rest and those under stress.

Glaucoma testing before CBG oil application

CBG oil

CBG has also shown some intriguing benefits in both animal and human trials. In patients with weak bladders, such as over 50s, it reduces bladder spasticity[24] and calms an overactive bladder. Several studies have looked at the benefits of cannabis for gut health and treating colitis and inflammatory bowel disease[25] as well.

Glaucoma is the leading cause of irreversible blindness in the world and is also a problem occurring in many individuals over the age of 50. Glaucoma[26] is an eye condition which causes pressure in the eye, also known as intraocular pressure (IOP). The eye produces a fluid known as aqueous humor that drains in the eye continuously. This means that if the fluid doesn’t circulate properly, it will build up and cause increased pressure in the eyeball. Glaucoma can also be a result of reduced blood supply to the optic nerve fibres. In fact, if it is not treated in the early stages, it may lead to a total loss of vision. The majority of the studies about glaucoma and canabidiol and canabigerol showed that CBD and CBG might be a viable and effective treatment with the help of the endocannabinoid system thanks to the fact that it reduces intraocular pressure[27], the primary cause of glaucoma. If you have any of these condition, you may see benefits with our CBG oils.

These are the Top 5 CBD products for 50+ year-olds and seniors

We bet you didn’t think CBD had so many positive effects for a wide range of conditions. If you have any of these conditions and you thought it couldn’t be helped with CBD, or you thought you were too old to be using it, then hopefully this article proved you wrong. CBD is a great product that can help with daily aches and pains often experienced in the over 50s as well as supplementing more serious conditions along with the correct treatments given by doctors. We hope you feel well informed by this article and you feel more comfortable taking the next step to purchasing a CBD product if you feel it could help.

References

  1. ‘An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies’ published in International Cannabinoid Research Society (2017) by Kerstin Iffland and Franjo Grotenhermen.
  2. ‘Safety and side effects of cannabidiol, a Cannabis sativa constituent’ published in Current Drug Safety (2011) by Mateus Machado Bergamaschi, Regina Helena Costa Queiroz, Antonio Waldo Zuardi and José Alexandre S Crippa.
  3. ‘Inhibitory effect of cannabidiol hydroxy-quinone, an oxidative product of cannabidiol, on the hepatic microsomal drug-metabolizing enzymes of mice’ published in the Journal of Pharmacobio-Dynamics (1991) by K Watanabe, N Usami, I Yamamoto and H Yoshimura.
  4. ‘Generation of reactive oxygen species during mouse hepatic microsomal metabolism of cannabidiol and cannabidiol hydroxy-quinone’ published in Life Sciences (2008) by Noriyuki Usami, Ikuo Yamamoto and Kazuhito Watanabe.
  5. ‘Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study’ published in Emerging Technologies and Therapeutics (2016) by Khalid A. Jadoon, Stuart H. Ratcliffe, David A. Barrett, E. Louise Thomas, Colin Stott, Jimmy D. Bell, Saoirse E. O’Sullivan and Garry D. Tan.
  6. ‘Endocannabinoid System Components: Overview and Tissue Distribution’ published in Advances in Experimental Medicine and Biology (2019) by Neal Joshi and Emmanuel S Onaivi.
  7. ‘Cannabinoids and Pain: New Insights From Old Molecules’ published in Front Pharmacology (2018) by Vučković S, Srebro D, Vujović KS, Vučetić Č and Prostran M.
  8. ‘The CB1 Endocannabinoid System Modulates Adipocyte Insulin Sensitivity’ published by the Obesity Society (2012) by Roja Motaghedi and Timothy E. McGraw.
  9. ‘The Effect of Phytocannabinoids on Airway Hyper-Responsiveness, Airway Inflammation, and Cough’ published in the Journal of Pharmacology and Experimental Therapeutics (2015) by Raj Makwana, Radhakrishnan Venkatasamy, Domenico Spina and Clive Page.
  10. ‘Endocannabinoid System in the Airways’ published in Molecular Diversity Preservation International (2019) by Turgut Emrah Bozkurt.
  11. ‘Cannabidiol improves lung function and inflammation in mice submitted to LPS-induced acute lung injury’ published in Immunopharmacology and Immunotoxicology (2014) by A Ribeiro, V I Almeida, C Costola-de-Souza, V Ferraz-de-Paula, M L Pinheiro, L B Vitoretti, J A Gimenes-Junior, A T Akamine, J A Crippa, W Tavares-de-Lima and J Palermo-Neto.
  12. ‘Hearing Loss as a Function of Aging and Diabetes Mellitus: A Cross Sectional Study’ published in PLOS ONE (2014) by In-Hwan Oh, Jong Hoon Lee, Dong Choon Park, MyungGu Kim, Ji Hyun Chung, Sang Hoon Kim and Seung Geun Yeo.
  13. ‘Tinnitus: causes and clinical management’ published in The Lancet. Neurology (2013) by Berthold Langguth, Peter M Kreuzer, Tobias Kleinjung and Dirk De Ridder.
  14. ‘Cannabis‐based medicines for chronic neuropathic pain in adults’ published in Cochrane Database of Systematic Reviews (2018) by Martin Mücke, Tudor Phillips, Lukas Radbruch, Frank Petzke and Winfried Häuser.
  15. ‘DMSO Represses Inflammatory Cytokine Production from Human Blood Cells and Reduces Autoimmune Arthritis’ published in PLOS ONE (2016) by Ingrid Elisia, Hisae Nakamura, Vivian Lam, Elyse Hofs, Rachel Cederberg, Jessica Cait, Michael R. Hughes, Leora Lee, William Jia, Hans H. Adomat, Emma S. Guns, Kelly M. McNagny, Ismael Samudio and Gerald Krystal.
  16. ‘Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis’ published in the European Journal of Pain (2016) by D.C. Hammell, L.P. Zhang, F. Ma, S.M. Abshire, S.L. McIlwrath, A.L. Stinchcomb and K.N. Westlund.
  17. ‘Pharmacology of DMSO’ published in Cryobiology (1986) by Stanley W. Jacob and Robert Herschler.
  18. ‘Cannabinoids and the expanded endocannabinoid system in neurological disorders’ published in Nature Reviews Neurology (2020) by Luigia Cristino, Tiziana Bisogno and Vincenzo Di Marzo.
  19. ‘Dimethyl Sulfoxide Induces Both Direct and Indirect Tau Hyperphosphorylation’ published in PLOS ONE (2012) by Carl Julien, François Marcouiller, Alexis Bretteville, Noura B. El Khoury, Joanie Baillargeon, Sébastien S. Hébert and Emmanuel Planel.
  20. ‘Molecular Targets of Cannabidiol in Neurological Disorders’ published in Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics (2015) by Clementino Ibeas Bih, Tong Chen, Alistair V. W. Nunn, Michaël Bazelot, Mark Dallas, and Benjamin J. Whalley.
  21. ‘Antioxidative and Anti-Inflammatory Properties of Cannabidiol’ published in Antioxidants (2019) by Sinemyiz Atalay, Iwona Jarocka-Karpowicz and Elzbieta Skrzydlewska.
  22. ‘Vasodilatory effects of cannabidiol in human pulmonary and rat small mesenteric arteries: modification by hypertension and the potential pharmacological opportunities’ published in the Journal of Hypertension (2020) by Baranowska-Kuczko Martaa, Kozłowska Hannaa, Kloza Monikaa, Sadowska Olgaa, Kozłowski Mirosławc, Kusaczuk Magdalenad, Kasacka Irenae and Malinowska Barbara.
  23. ‘A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study’ published in JCI Insight (2017) by Khalid A. Jadoon, Garry D. Tan and Saoirse E. O’Sullivan.
  24. ‘Effect of Non-psychotropic Plant-derived Cannabinoids on Bladder Contractility: Focus on Cannabigerol’ published in Natural Product Communications (2015) by Ester Pagano, Vittorino Montanaro, Antonio Di Girolamo, Antonio Pistone, Vincenzo Altieri, Jordan K Zjawiony, Angelo A Izzo and Raffaele Capasso.
  25. ‘Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease’ published in Biochemical Pharmacology (2013) by Francesca Borrelli, Ines Fasolino, Barbara Romano, Raffaele Capasso, Francesco Maiello, Diana Coppola, Pierangelo Orlando, Giovanni Battista, Ester Pagano, Vincenzo Di Marzo and Angelo A. Izzo.
  26. ‘Should ophthalmologists recommend medical cannabis to patients with glaucoma?’ published in the Journal of the Danish Medical Association (2018) by Zaynab Ahmad Mouhammad and Miriam Kolko.
  27. ‘A Comparison of the Ocular and Central Effects of Δ9-Tetrahydrocannabinol and Cannabigerol’ published in Journal of Ocular Pharmacology and Therapeutics (2009) by Brenda K. Colasanti.